- Home
- SION vs ANAB Comparison
SION vs ANAB Comparison
Compare SION & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SION
- ANAB
- Stock Information
- Founded
- SION 2019
- ANAB 2005
- Country
- SION United States
- ANAB United States
- Employees
- SION N/A
- ANAB N/A
- Industry
- SION
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- SION
- ANAB Health Care
- Exchange
- SION NYSE
- ANAB Nasdaq
- Market Cap
- SION 564.4M
- ANAB 621.1M
- IPO Year
- SION 2025
- ANAB 2017
- Fundamental
- Price
- SION $14.49
- ANAB $23.17
- Analyst Decision
- SION Strong Buy
- ANAB Buy
- Analyst Count
- SION 1
- ANAB 10
- Target Price
- SION $32.00
- ANAB $44.25
- AVG Volume (30 Days)
- SION 124.0K
- ANAB 760.3K
- Earning Date
- SION 05-12-2025
- ANAB 08-04-2025
- Dividend Yield
- SION N/A
- ANAB N/A
- EPS Growth
- SION N/A
- ANAB N/A
- EPS
- SION N/A
- ANAB N/A
- Revenue
- SION N/A
- ANAB $111,872,000.00
- Revenue This Year
- SION N/A
- ANAB N/A
- Revenue Next Year
- SION N/A
- ANAB $24.39
- P/E Ratio
- SION N/A
- ANAB N/A
- Revenue Growth
- SION N/A
- ANAB 387.20
- 52 Week Low
- SION $7.26
- ANAB $12.21
- 52 Week High
- SION $25.19
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- SION N/A
- ANAB 56.01
- Support Level
- SION N/A
- ANAB $22.46
- Resistance Level
- SION N/A
- ANAB $24.17
- Average True Range (ATR)
- SION 0.00
- ANAB 1.72
- MACD
- SION 0.00
- ANAB -0.01
- Stochastic Oscillator
- SION 0.00
- ANAB 73.23
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).